Patent ID: 8562986

Claim:
An engineered recombinant anti-αv integrin antibody comprising: (i) the light chain CDR regions: CDR1: RASQDISNYLA (SEQ ID No. 7), CDR2: YTSKIHS (SEQ ID No. 8), and CDR3: QQGNTFPYT (SEQ ID No. 9); (ii) the heavy chain CDR regions: CDR1: SFWMH (SEQ ID No. 10), CDR2: YINPRSGYTEYNEIFRD (SEQ ID No. 11), and CDR3: FLGRGAMDY (SEQ ID No. 12); (iii) the light chain framework regions: FR-1: DIQMTQSPSSLSASVGDRVTITC (SEQ ID No. 14), FR-2: WYQQKPGKAPKLLIY (SEQ ID No. 15), FR-3: GVPSRFSGSGSGTDYTFTISSLQPEDIATYYC (SEQ ID No. 16), and FR-4: FGQGTKVEIK (SEQ ID No. 17) (iv) the heavy chain framework regions: FR1: QVQLQQSGGELAKPGASVKVSCKASGYTFS (SEQ ID No. 22), FR2: WVRQAPGQGLEWIG (SEQ ID No. 23), FR3: KATMTTDTSTSTAYMELSSLRSEDTAVYYCAS (SEQ ID No. 24), and FR4: WGQGTTVTVSS (SEQ ID No. 25); and (v) a heavy chain constant region derived from human IgG and a human constant light chain region.